<!DOCTYPE html>
<HTML>
    <HEAD>
    <TITLE>COVISHIELD</TITLE>
    </HEAD>
    <body style ="background:url(./img/HEADER\ 4.jpg); background-size: 100%; background-repeat: no-repeat;" >
        <header>
            <a href="./index.html"><img src="./img/LOGO COLOUR.png" alt="LOGO" height="150px"></a>
            <nav style="float:right">
            <br><br><br>
            <a href="./VACCINE.HTML" style="color: black; text-decoration: none;">HOME</a> &nbsp;&nbsp;
            <a href="./COVAXIN.HTML" style="color: black; text-decoration: none;">COVAXIN</a> &nbsp;&nbsp;
            <a href="./COVISHIELD.HTML" style="color: black; text-decoration: none;">COVISHIELD</a>&nbsp;&nbsp;
            <a href="./SPUTNIK-V.HTML" style="color: black; text-decoration: none;">SPUTNIK-V</a>&nbsp;&nbsp;
            </nav>     
        </header>
    <center><h1 style="font-size: 50px;color: rgb(243, 82, 82);"><b>COVISHIELD</b></h1>
    
    <br><br><br>
    <img src="./img/COVISHIELD.jpg" height="300" width="500" border="2" > </center>
    <br><br>
    <p style="font-size: 19px;font-weight: 700;color: rgb(31, 30, 30);">The CoviShield COVID-19 (AZD1222) (C19VAZ) vaccine, formerly known as ChAdOx1 nCoV-19, is made from a virus (ChAdOx1), a weakened version of a common cold virus (adenovirus). In addition, genetic material has been added to the ChAdOx1 construct, which is used to make proteins from the SARS-CoV-2 coronavirus called Spike glycoprotein (S). </p>
    <p style="font-size: 19px;font-weight: 700;color: rgb(31, 30, 30);">The WHO granted Emergency Use Listing (EUL) to the AstraZeneca - Oxford COVID-19 vaccine 'COVISHIELD' ChAdOx1-S [recombinant] manufactured by Serum Institute of India on February 15, 2021. WHOâ€™s EUL assesses the quality, safety, and efficacy of COVID-19 vaccines and is a prerequisite for COVAX Facility vaccine supply, enabling countries to expedite their regulatory approval to import and administer COVID-19 vaccines.</p>

    <BR>
    </BODY>
    </HTML>